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Abstract
Background: In rheumatoid arthritis (RA) bone marrow edema (BME, osteitis) and anti-citrullinated protein antibodies
(ACPA) are associated with radiographic progression. ACPA have been associated with BME, but it is unknown if this
association is confined to ACPA and BME. We performed cross-sectional analysis of the association of ACPA,
rheumatoid factor (RF) and anti-carbamylated protein (anti-CarP) antibodies with BME and other types of
inflammation (synovitis, tenosynovitis) detected by magnetic resonance imaging (MRI).
Methods: Disease-modifying antirheumatic drug (DMARD)-naïve patients with early arthritis (n = 589), included in
the Leiden Early Arthritis Clinic cohort, underwent contrast-enhanced 1.5 T MRI of unilateral wrist, metacarpophalangeal
and metatarsophalangeal-joints at baseline. BME, synovitis and tenosynovitis were scored by two readers. ACPA,
rheumatoid factor (RF) and anti-CarP were determined at baseline.
Results: In univariable analyses ACPA-positive patients had higher BME scores than ACPA-negative patients
(median 4.5 vs. 2.0, p < 0.001), but not more synovitis and tenosynovitis. Also RF (median 3.75 vs. 2.0, p < 0.001)
and anti-CarP antibodies (median 3.5 vs. 2.5, p = 0.012) were associated with higher BME scores. Because the
autoantibodies were concomitantly present, analyses were stratified for the presence of different autoantibody
combinations. ACPA-positive (ACPA+), RF-negative (RF-), anti-CarP-negative (anti-CarP-) patients did not have
higher BME-scores than ACPA-negative (ACPA-), RF-, anti-CarP- patients. However ACPA+, RF-positive (RF+), anti-
CarP- patients and ACPA+, RF+, anti-CarP-positive (anti-CarP+) patients had higher BME scores than ACPA-, RF-,
anti-CarP- patients (median 5.0 and 4.5 vs. 2.0, p < 0.001 and p < 0.001). ACPA levels were not associated with BME
scores. Analyses within RA- and UA-patients revealed similar results.
Conclusions: The presence of ACPA alone or ACPA level was not statistically significantly associated with BME
scores, but the combined presence of ACPA and RF was associated with more BME. This suggests an additive role
of RF to ACPA in mediating osteitis.
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Background
Rheumatoid arthritis (RA) is characterized by chronic
inflammation of the joints that may result in progressive
structural damage. Magnetic resonance imaging (MRI)
detects inflammation sensitively [1]. Whereas synovitis
and tenosynovitis can also be evaluated by other imaging
modalities, such as ultrasound, MRI is the only modality
that depicts bone marrow edema (BME). Histopathology
studies in RA have shown that BME lesions consist of
infiltration by leucocytes and an increased number of
osteoclasts [2–4]. Therefore, BME has also been named
osteitis. These data suggest a link between BME and
structural damage in RA. Indeed, the importance of
BME is supported by several studies showing that BME
is a predictor of radiographic evidence of progression
[5–13]. A recent study even showed that the persisting
presence of BME is associated with an odds ratio (OR)
of 60 for erosive progression at the same location [14].
In addition to BME, anti-citrullinated protein antibodies
(ACPA) are also a strong predictor of radiographic pro-
gression [15–23]. Up to two-thirds of patients with RA
harbor ACPA, as has been known for many years [24].
However, the underlying mechanism linking ACPA with a
more severe disease progression with increased joint de-
struction is incompletely elucidated. Recent data suggest
that ACPA influences bone resorption by directly activat-
ing osteoclasts [25]. The combination of these findings lead
us to hypothesize that ACPA are associated with BME.
Other studies, including a small study that we performed
previously suggest there is association between BME and
ACPA [26, 27]. However, ACPA are often simultaneously
present with other RA-related autoantibodies such as
rheumatoid factor (RF) and anti-carbamylated protein anti-
bodies (anti-CarP) (which also have been associated with
radiographic destruction) [28–30]. To our knowledge the
effects of different autoantibodies (either alone or in com-
bination) on BME are unknown. Furthermore, the associ-
ation between different autoantibodies and other types of
inflammation detected by MRI (synovitis and tenosyno-
vitis) has never been thoroughly explored. Therefore, this
cross-sectional study aimed to investigate the associations




The 589 patients with early arthritis were consecutively
included in the Leiden Early Arthritis Clinic (EAC) be-
tween 2010 and 2014. The EAC is an inception cohort
that includes patients attending the rheumatologist who
present with clinically confirmed arthritis and symptom
duration of <2 years. Patients were disease-modifying-
antirheumatic-drug (DMARD)-naïve at inclusion. The
cohort started in 1993. MRI was performed from 2010
onwards; 598 patients underwent MRI, and 9 were ex-
cluded from analysis because no contrast agent was ad-
ministered. The median interval between inclusion in
the study and MRI was 1.3 weeks. Questionnaires were
administered, and joint counts and blood samples were
collected at baseline [31]. Baseline serum samples were
tested for ACPA (anti-CCP2, Eurodiagnostica, Arnhem,
the Netherlands, cutoff value ≥7 U/ml), IgM RF (as de-
scribed previously, in-house ELISA [32]) and IgG anti-CarP
antibodies against carbamylated fetal calf serum (FCS).
Anti-CarP was determined as described previously [28]; the
cutoff for positivity for anti-CarP was based on the mean
plus two times the standard deviation from a set of 204
healthy controls. One year after presentation, 183 patients
fulfilled the 1987 criteria for RA [33], 214 had undiffer-
entiated arthritis (UA) and 192 had other forms of arth-
ritis, including psoriatic arthritis, reactive arthritis and
others (Table 1).
Magnetic resonance imaging and scoring
At baseline, MRI was performed of the metacarpopha-
langeal (MCP), wrist and metatarsophalangeal (MTP)
joints on the most painful side or on the dominant side
in the case of symmetric symptoms. MRI was performed
using an MSK Extreme 1.5 T extremity MRI system. In
the wrist and MCP joints a coronal T1-weighted sequence
was acquired before intravenous injection of contrast
agent (gadoteric acid). Post-contrast, coronal and axial
T1-weighted sequences with frequency-selective fat satur-
ation were obtained. The forefoot was scanned using a
T1-weighted sequence and a T2-weighted fat-saturated se-
quence in the axial plane. The protocol was shortened
after 371 patients had been imaged [34]. For post-contrast
imaging of the foot in the remaining 218 patients,
T1-weighted, fat-saturated sequences were obtained
in the coronal and axial plane and the T2-weighted
sequence was deleted. A more detailed description of
the scan protocol is provided elsewhere [14, 35, 36]
and in Additional file 1.
BME and synovitis were scored semi-quantitatively ac-
cording to the rheumatoid arthritis MRI scoring system
(RAMRIS) [37], with the exception that BME was
assessed on a contrast-enhanced T1-weigthed fat-suppressed
sequence. Previous studies have shown that T2-weighted
fat-saturated sequences and contrast-enhanced T1-weighted
fat-saturated images perform equally well in the depiction of
BME [34, 38, 39], and according to the European Society of
Musculoskeletal Radiology (ESSR), both sequences can be
used to evaluate BME [40]. The T1-sequence was used as it
allowed a shorter scan time. In addition, tenosynovitis in the
wrist and MCP joints was scored according to the method
proposed by Haavardsholm et al. [41], with tenosynovitis
assessed for the flexor and extensor tendons of MCP joints
2–5 using the same scale of 0–3 as for the wrist. MR images
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were scored by two readers blinded to any clinical data. The
mean total scores of both readers for BME, synovitis and
tenosynovitis were used in further analyses. The intra-reader
class correlation coefficients for the total inflammation score
based on 40 MR images that were scored twice, were 0.98
and 0.93, respectively. Based on all 598 scans, the inter-
reader class correlation coefficient for the total inflammation
score was 0.95.
Sensitivity analyses
Our primary analyses were performed in all 589 early
arthritis patients, as we hypothesized that direct associ-
ation between autoantibodies and MRI-detected inflam-
mation, if present, would be independent of the clinical
diagnosis. However, analyses were repeated in the sub-
group of 397 patients classified with UA or RA according
to the 1987 American College of Rheumatology (ACR)
criteria. Patients who had UA after one year were included
in these analyses because misclassification could have oc-
curred due to DMARD treatment during the first year
that could have hampered progression to fulfilling the
1987 criteria for RA. As some of these patients with UA
would have progressed to RA without treatment (but now
remain unclassified), we also studied the patients with UA.
Statistical analysis
The t test, multivariable linear regression, and multivari-
able logistic regression were used for analysis as appro-
priate. In multivariable linear regression analysis, the
BME scores were log10-transformed (log10(score + 1)) to
approximate a normal distribution. For interpretation,
the obtained effect size (beta) was back-transformed to
the normal score. All models were adjusted for age,
gender and symptom duration. Baseline data on ACPA,
RF, and anti-CarP were dichotomized (seropositive vs.
seronegative). Anti-CarP data were missing for 16 pa-
tients. ACPA and RF status was known for all patients. To
determine the effect of ACPA levels on BME, baseline
ACPA was categorized into three groups within ACPA-
positive patients based on the range of ACPA values
(low, intermediate, or high); the thresholds were: ≥7 U/ml,
≥167 U/ml and ≥327 U/ml. P values ≤0.05 were consid-




Baseline characteristics of the 589 patients are presented
in Table 1.
ACPA is associated with BME at baseline
We first evaluated whether patients with ACPA (n = 141)
or without ACPA (n = 448) had differences in BME scores
(Fig. 1a). ACPA-positive patients had higher BME scores
(median = 4.5) than ACPA-negative patients (median = 2.0,
p < 0.001). We subsequently questioned whether ACPA is
also associated with other types of MRI-detected inflam-
mation, i.e., synovitis and tenosynovitis. There were no
Table 1 Baseline characteristics of the total group of patients with early arthritis and the subgroups of patients with rheumatoid
arthritis (RA) or undifferentiated arthritis (UA)
Variable All patients with early arthritis Subgroup of patients with RA or UA
(n = 589) (n = 397)
Age, mean (sd) 54.8 (16) 54.9 (15)
Female, n (%) 363 (62) 253 (64)
Symptom duration, median (IQR), weeks 12.6 (5–27) 12.2 (5–26.2)
TJC, median (IQR) 4 (2–7) 4 (2–6)
SJC, median (IQR) 3 (2–7) 3 (2–7)
CRP (mg/L), median (IQR) 5.7 (3–17) 6 (3–17)
ACPA positivity, n (%) 141 (24) 123 (31)
RF positivity, n (%) 193 (33) 151 (38)
anti-CarP positivity, n (%) 88 (15) 71 (18)
Total RAMRIS, median (IQR) 12.5 (5.5–24) 13.5 (6–24)
Total BME score, median (IQR) 2.5 (1–6) 2.5 (1–6)
Total synovitis score, median (IQR) 3.5 (1–7.5) 4 (1.5–8)
Total tenosynovitis score, median (IQR) 2 (0–6) 3 (0.5–6)
The diagnoses of the 589 patients with early arthritis were: 183 RA (according to the 1987 RA criteria), 214 UA, 14 reactive arthritis, 14 gout, 2 pseudogout, 30
psoriatic arthritis, 35 inflammatory osteoarthritis, 4 Lyme’s arthritis, 1 paramalignant arthritis, 3 systemic lupus erythematosus, 11 other systemic disorder, 7 mixed
connective tissue disease, vasculitis, 4 sarcoidosis, 9 spondyloarthritis, 8 remitting seronegative symmetrical synovitis with pitting edema, and 50 other unspecified
conditions. n number of patients, sd standard deviation, IQR interquartile range, symptom duration time between symptom onset and inclusion in cohort, TJC 68
tender joint count, SJC 66 swollen joint count, CRP C-reactive protein, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor, anti-CarP anti-carbamylated
protein antibodies, RA/UA subgroup of patients with rheumatoid arthritis (according to the 1987 RA criteria) or undifferentiated arthritis
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statistically significant differences in synovitis or tenosyno-
vitis scores in ACPA-positive and ACPA-negative patients
(Fig. 1a). Similar results were obtained for BME when only
patients with RA and UA were studied (ACPA-positive
median = 3.5, ACPA-negative median = 2.0, p = 0.001) and
no statistically significant differences were observed for
synovitis and tenosynovitis (Additional file 2: Figure S1A).
Based on these data ACPA seemed to be primarily associ-
ated with BME.
RF and anti-CarP antibodies are also associated with BME
We were also interested in whether RF and anti-CarP
antibodies are also associated with more severe BME.
The BME scores were higher in RF-positive patients
(median = 3.75) compared to RF-negative patients
(median = 2.0, p < 0.001, Fig. 1b). Similarly, BME scores
were also higher in anti-CarP-positive than in anti-CarP-
negative patients (median = 3.5 vs. 2.5, p = 0.012, Fig. 1c).
Besides BME, synovitis and tenosynovitis scores were
also higher in RF-positive than in RF-negative patients
(synovitis: median 4.5 vs. 3.0, p = 0.001; tenosynovitis:
median 3.5 vs. 1.5, p = 0.004). Synovitis and tenosynovitis
scores were also higher in anti-CarP-positive than in
anti-CarP-negative patients (synovitis: median = 4.75 vs.
3.5, p = 0.021; tenosynovitis: median = 4.25 vs. 1.5, p =
0.013). In patients with RA and UA only the BME scores
Fig. 1 Illustration of the association between anti-citrullinated protein antibodies (ACPA) (a), rheumatoid factor (RF) (b) and anti-carbamylated
protein antibodies (anti-CarP) (c), and magnetic-resonance-imaging-detected bone marrow edema (BME), synovitis and tenosynovitis scores in
early arthritis (n = 589). Horizontal lines represent median. Whiskers show the 10th–90th percentile. Dots represent outliers. a BME: p ≤ 0.001;
synovitis: p = 0.084; tenosynovitis: p = 0.064. b BME: p ≤ 0.001; synovitis: p = 0.001; tenosynovitis: p = 0.004. c BME: p ≤ 0.012; synovitis: p = 0.021;
tenosynovitis: p = 0.013. Total score: sum of scores in metacarpophalangeal, wrist, and metatarsophalangeal joints. *Significant difference (p < 0.05)
between autoantibody-negative and autoantibody-positive patients
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were significantly higher in RF-positive (RF+) or anti-
CarP-positive (anti-CarP+) patients, but synovitis and
tenosynovitis scores were not statistically significantly
different (BME: RF+ median = 3.5, RF-negative (RF-) me-
dian = 2.0, p = 0.002; anti-CarP+ median = 3.5, anti-CarP-
negative (anti-CarP-) median = 2.5, p = 0.017, Additional
file 2: Figure S1B, C).
Patients can concurrently have BME, synovitis, and
tenosynovitis. To unravel the independent association
between RF and BME, synovitis, and tenosynovitis scores,
multivariable logistic regression analysis was performed
with RF as the dependent variable and BME, synovitis,
and tenosynovitis as independent variables. The same was
done with anti-CarP as the dependent variable. In early
arthritis, only the BME score was independently associ-
ated with RF (p < 0.001) or with anti-CarP (p = 0.003).
Similar results were observed in the subgroup of patients
with RA or UA, in whom only BME was associated with
RF (p < 0.001) or with anti-CarP (p = 0.001). Thus, these
multivariable analyses suggest that the BME score is inde-
pendently associated with RF or anti-CarP, in contrast to
the synovitis and tenosynovitis scores. Because of this re-
sult, and because it was observed that there was an associ-
ation between BME and ACPA, subsequent analyses
focused on BME.
ACPA and RF are both independently associated with BME
Patients frequently have a combination of different types of
inflammation, and also concomitantly have the three auto-
antibodies. For more insight into the relationship between
the different autoantibodies and BME, multivariable linear
regression analysis was performed with BME as the out-
come and the three autoantibodies as independent vari-
ables. Both ACPA and RF were significantly associated
with BME (ACPA: p = 0.015, beta = 1.33, indicating that
ACPA-positive (ACPA+) patients had 33 % higher BME
scores than ACPA-negative (ACPA-) patients; RF: p = 0.004,
beta = 1.31, indicating that RF+ patients had 31 % higher
BME scores than RF- patients). Additional adjustments for
CRP and SJC produced similar results (ACPA: p = 0.009,
beta = 1.36; RF: p = 0.001, beta = 1.36). In a similar analysis
in the subgroup of patients with RA and UA, there was a
trend towards significance for ACPA (p = 0.091, beta =
1.26) and a significant result for RF (RF: p = 0.022, beta =
1.31). Thus, together these data indicated that ACPA and
RF are independently associated with BME scores.
Combined presence of ACPA and RF is associated with BME
The multivariable analyses described above did not
evaluate different effects for combinations of antibodies.
Different autoantibody combinations were compared for
more insight into the effect of individual antibodies and
a combination of antibodies on BME (Fig. 2). In the ab-
sence of both RF and anti-CarP, ACPA was not associated
with BME (ACPA+, RF-, anti-CarP- patients vs. ACPA-,
RF-, anti-CarP- patients, median 1.0 vs. 2.0, p = 0.43). Also
the presence of RF or anti-CarP alone was not associated
with BME (ACPA-, RF+, anti- CarP- patients and ACPA-,
RF-, anti-CarP+ patients vs. ACPA-, RF-, anti-CarP- pa-
tients, median 2.5 and 1.5 vs 2.0 respectively, p = 0.096
and p = 0.43). However ACPA+, RF+, anti-CarP- patients
and ACPA+, RF+, anti-CarP+ patients did have signifi-
cantly higher BME-scores than ACPA-, RF-, anti-CarP-
patients (median 5.0 and 4.5 vs. 2.0 respectively, p < 0.001
and p < 0.001). The same analysis in only RA- and UA-
patients showed that ACPA+, RF+, anti-CarP- patients
and ACPA+, RF+, anti-CarP+ patients had higher BME-
scores than ACPA-, RF-, anti-CarP- patients (median 4.5
and 4.5 vs. 2.0 respectively, p < 0.001 and p < 0.001, Fig. 3).
Thus only the combined presence of ACPA and RF (with
or without the presence of anti-CarP) was associated with
higher BME-scores.
ACPA level is not associated with BME
In general, patients who carry different RA-related auto-
antibodies also have higher levels of ACPA [42]. In our
Fig. 2 Bone marrow edema (BME) scores in patients with early
arthritis (n = 589) with different combinations of anti-citrullinated
protein antibodies (ACPA), rheumatoid factor (RF) and anti-
carbamylated protein antibodies (anti-CarP). Horizontal lines repre-
sent median. Whiskers show the 10th–90th percentile. Dots represent
outliers. ACPA+, RF+, anti-CarP- patients vs. ACPA-, RF-, anti-CarP- pa-
tients, p < 0.001; ACPA+, RF+, anti-CarP+ patients vs. ACPA-, RF-, anti-
CarP- patients, p < 0.001. ACPA-, RF-, anti-CarP- patients, n = 353;
ACPA-, RF+, anti-CarP- patients, n = 68; ACPA+, RF-, anti-CarP- pa-
tients, n = 15; ACPA+, RF+, anti-CarP- patients, n = 48; ACPA-, RF-,
anti-CarP+ patients, n = 11; ACPA-, RF+, anti-CarP+ patients, n = 3;
ACPA+, RF-, anti-CarP+ patients, n = 5; ACPA+, RF+, anti-CarP+ pa-
tients, n = 69. Total score: sum of BME scores in metacarpophalan-
geal, wrist, and metatarsophalangeal joints. *Significant difference
(p < 0.05) between subgroups
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present data we also observed higher ACPA levels in pa-
tients who also carried RF and anti-CarP (ACPA+, RF-, anti-
CarP- patients median 116 U/ml, ACPA+, RF+, anti-CarP-
patients median 155 U/ml, ACPA+, RF-, anti-CarP+ patients
median 92 U/ml, ACPA+, RF+, anti-CarP+ patients median
257 U/ml, p = 0.020). This prompted us to explore whether
the combined presence of ACPA and RF with higher BME
scores could be explained by higher ACPA levels. To in-
vestigate the association between BME and ACPA
levels, ACPA were studied as continuous data (Add-
itional file 3: Figure S2) and divided into three sub-
groups. The BME scores observed in these ACPA
categories were not different (Fig. 4). Similarly, no dif-
ferences were observed when analyzing the BME scores
in relation to ACPA levels in patients with RA and UA
(Additional file 4: Figure S3). These data suggest that it
is the combined presence of ACPA and RF that is asso-
ciated with BME, rather than ACPA levels.
Combined presence of ACPA, RF and anti-CarP is associated
with synovitis and tenosynovitis
The analyses focused on BME as the different autoanti-
bodies were not associated with synovitis or tenosynovitis
scores in univariable analyses (for ACPA) or in multivari-
able analyses (for RF and anti-CarP). However, having ob-
served that higher BME scores were primarily associated
with the combined presence of ACPA and RF (and not
with the presence of a single antibody), we reasoned that
it might also be possible that antibodies were not individu-
ally associated with synovitis or tenosynovitis scores, but
that some combinations of autoantibodies were associated
with synovitis or tenosynovitis scores. To study this, we
finally assessed the association between different com-
binations of autoantibodies and synovitis and tenosyno-
vitis (Fig. 5). ACPA+, RF+, anti-CarP+ patients had
higher synovitis scores than ACPA-, RF-, anti-CarP- pa-
tients (median 5.0 vs. 3.0, p = 0.001). For tenosynovitis,
ACPA+, RF+, anti-CarP+ patients had higher scores
than ACPA-, RF-, anti-CarP- patients (median 4.5 vs.
1.0, p < 0.001), and ACPA+, RF+, anti-CarP+ patients
had higher scores than ACPA+, RF+, anti-CarP- patients
(median 4.5 vs. 3.5 p = 0.039). Thus, the combined pres-
ence of ACPA, RF and anti-CarP was associated with the
highest synovitis and tenosynovitis scores.
Fig. 3 Bone marrow edema (BME) scores in patients with rheumatoid
arthritis (RA) and undifferentiated arthritis (UA) (n=397) with different
combinations of anti-citrullinated protein antibodies (ACPA), rheumatoid
factor (RF) and anti-carbamylated protein antibodies (anti-CarP).
Horizontal lines representing median. Whiskers show the 10th–
90th percentile. Dots represent outliers. ACPA+, RF+, anti-CarP+
patients vs. ACPA-, RF-, anti-CarP- patients, p < 0.001; ACPA+, RF+,
anti-CarP- patients vs. ACPA-, RF-, anti-CarP- patients, p < 0.001.
ACPA-, RF-, anti-CarP- patients, n = 217; ACPA-, RF+, antiCarP-
patients, n = 43; ACPA+, RF-, anti-CarP- patients, n = 14; ACPA+,
RF+, anti-CarP- patients, n = 42; ACPA-, RF-, anti-CarP+ patients,
n = 6; ACPA-, RF+, anti-CarP+ patients, n = 1; ACPA+, RF-, anti-
CarP+ patients, n = 3; ACPA+, RF+, anti- CarP+ patients, n = 61.
Total score: sum of BME scores in metacarpophalangeal, wrist,
and metatarsophalangeal joints. *Significant difference between
subgroups (p < 0.05)
Fig. 4 Bone marrow edema (BME) scores in anti-citrullinated protein
antibodies (ACPA)-positive patients with early arthritis (n = 141) with
low, intermediate, or high levels of ACPA. Horizontal lines represent
median. Whiskers show the 10th–90th percentile. Dots represent
outliers. Baseline ACPA is shown categorically as low, intermediate, or
high. The groups were as follows: low ≥7 U/ml, intermediate ≥167 U/ml
and high ≥327 U/ml. Low: n = 64; intermediate: n = 32; high: n = 45.
Kruskal-Wallis test, p= 0.14
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Discussion
The relationship between ACPA and other RA-related
autoantibodies and BME was subject of this study. We
showed that ACPA, RF and anti-CarP antibodies were
all associated with BME in univariable analyses. How-
ever, when the different autoantibody combinations were
compared, the presence of ACPA alone was not associ-
ated with BME, but the combined presence of ACPA
and RF (with or without anti-CarP) was associated with
BME. The level of ACPA was not associated with BME,
suggesting that this cannot be explained by ACPA levels
but rather by the combined presence of ACPA and RF.
To our knowledge this is the first study including al-
most 600 MR images in which the relationship between
the different autoantibodies and MRI-detected inflamma-
tion was investigated in detail. Due to this large sample size
it was possible to evaluate the independent associations be-
tween BME and ACPA, RF and anti-CarP. Furthermore, it
was possible to investigate the differential effects of the
autoantibodies on the different types of MRI-detected in-
flammation. On analyses in subgroups of patients with dif-
ferent autoantibody combinations the BME scores were
mainly increased when both ACPA and RF were present.
Our data suggest a potential interaction between RF and
ACPA; however, the underlying mechanism by which
ACPA and RF could act in concert was not studied. Po-
tentially RF could have an immune-enhancing effect by
crosslinking immune complexes and thereby activate
monocytes or macrophages and induce cytokine ex-
pression. This is supported by a recent study that
showed that RF augments TNFα production by ACPA
immune complexes in vitro [43]. Another explanation
could be that RF has a role in immune complex
stabilization. ACPA bind to target antigens with low
avidity but it could well be that when RF is also involved
in the immune complex this binding is more stable.
Further fundamental studies should be performed for
more insight into the interaction between these two
autoantibodies.
This study investigated local inflammation as observed
on MRI. Recently the combined effect of ACPA and RF
on systemic inflammation was investigated in RA,
showing that the combined presence of ACPA and RF
was associated with higher levels of pro-inflammatory
cytokines and increased acute phase reactants and dis-
ease activity [43]. We also analyzed the association be-
tween the different autoantibody combinations and
CRP, erythrocyte sedimentation rate (ESR), SJC and 28-
joint-count disease activity score (DAS28) as measures
of disease activity in our patients with RA or UA at
baseline; no large differences were observed but patients
positive for all three autoantibodies had the highest dis-
ease activity scores (Additional file 5: Figure S4).
Association between the combined presence of auto-
antibodies and BME was observed. Since BME is associ-
ated with erosive progression [5–14], it would be
interesting to investigate whether combinations of auto-
antibodies are also associated with radiographic pro-
gression. The association between ACPA or RF and
radiographic progression is well-investigated [15–23].
However the number of studies investigating the com-
bined effect of ACPA and RF is limited. A recent study
Fig. 5 Scores for synovitis detected by magnetic resonance imaging (a) and tenosynovitis (b) in patients with early arthritis (n = 589) with
different combinations of anti-citrullinated protein antibodies (ACPA), rheumatoid factor (RF) and anti-carbamylated protein antibodies (anti-CarP).
Horizontal lines represent median. Whiskers show the 10th–90th percentile. Dots represent outliers. Synovitis: ACPA+, RF+, anti-CarP+ patients vs.
ACPA-, RF-, anti-CarP- patients, p < 0.001. Tenosynovitis: ACPA+, RF+, anti-CarP+ patients vs. ACPA-, RF-, anti-CarP- patients, p < 0.001; ACPA+, RF+,
anti-CarP+ patients vs. ACPA+, RF+, anti-CarP- patients, p = 0.039. ACPA-, RF-, anti-CarP- patients, n = 353; ACPA-, RF+, anti-CarP- patients, n = 69;
ACPA+, RF-, anti-CarP- patients, n = 15; ACPA+, RF+, anti-CarP- patients, n = 48; ACPA-, RF-, anti-CarP+ patients, n = 11; ACPA-, RF+, anti-CarP+ patients,
n = 3; ACPA+, RF-, anti-CarP+ patients, n = 5; ACPA+, RF+, anti-CarP+ patients, n = 69. Total score: sum of scores in metacarpophalangeal,
wrist, and metatarsophalangeal joints. *Significant difference between subgroups (p < 0.05)
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in two cohorts showed no additive effect of RF on
radiographic progression in ACPA-positive patients
[44]. Another study analyzing high-resolution peripheral
quantitative computed tomography (CT) images of the
MCP joints in patients with RA showed that there was an
additive effect of ACPA and RF on erosion number and
size [45]. The read-out of these studies (microCT and
conventional radiography) was different. It would be in-
teresting to further unravel the association between differ-
ent autoantibody combinations and erosive progression in
further observational studies.
A limitation of the subgroup analysis is that some
autoantibody combinations were infrequent and so no
definite conclusions can be drawn for these. For instance,
patients who were ACPA+, RF-, anti-CarP- were infre-
quent. Despite the limited power, there was no tendency
in the data towards higher BME scores in these patients
compared to the triple-negative group. This study is not
the first that did not identify a deleterious effect of the
presence of ACPA alone. Two recent papers reported on
mice that were injected with ACPA, and although ACPA
was detected in the joint, no signs of inflammation
were observed in the synovium [46, 47]. Surprisingly, in
our data the presence of ACPA alone even had a non-
significant tendency towards a protective effect against
synovitis (in all patients with early arthritis patients and
in patients with RA or UA). Interestingly, two recent
studies in humans showed that the presence of ACPA
without RF was associated with lower disease activity
[42, 43]. In summary, further larger studies are needed
to determine the role of ACPA single positivity.
Another limitation could be that we used contrast-
enhanced T1-weighted images to assess BME. Using the
RAMRIS method, T2-weighted fat-suppressed sequences,
or when this sequence is not available, a short tau inversion
recovery (STIR) sequence, should be used to assess BME.
However, it has been demonstrated that a contrast-
enhanced T1-weighted fat-suppressed sequence performed
equally well to depict BME as a T2-weighted fat-
suppressed sequence [34, 38, 39] and the evaluation of
BME on a T1-weighted fat suppressed sequence is also
supported by the ESSR [40]. In this study the contrast-
enhanced T1-weighted fat-suppressed sequence was
used because it allowed a shorter scan time and has a
higher signal-to-noise ratio [34, 38].
A third limitation is that the scan protocol for the
foot was changed. When the analyses of the different
autoantibody combinations and BME scores in pa-
tients with early arthritis were repeated separately in
the patients scanned with or without the coronal se-
quence of the foot, the presence of ACPA alone was not
associated with higher BME scores, but the combined
presence of ACPA and RF was associated with higher BME
scores (data not shown). This suggests that the change in
scan protocol for the foot had no major influences on the
results of this study.
Finally, our arthritis cohort includes patients with early
disease who presented with different diagnoses. We hy-
pothesized that direct association between ACPA and
MRI-detected inflammation would be independent of
the clinical diagnosis. However, to exclude an effect of
this heterogeneity in patient selection on our findings
we repeated all analyses within the subgroup of patients
with RA and UA. This produced similar results.
Of note, the differences observed in BME scores were
statistically significant but the absolute differences were
relatively small. The variation in BME scores was only
partly explained by the autoantibody status. Nonetheless
the present study does increase our understanding of the
relationship between autoantibodies and BME, which
are both predictors of radiographic progression. The
observation that ACPA is associated with osteitis, only
when RF is present, fuels further laboratory studies on
the biological relevance of these autoantibodies.
Conclusions
In conclusion, the presence of ACPA alone and ACPA
serum levels were not associated with BME scores. How-
ever, BME scores were higher when patients were seroposi-
tive for both ACPA and RF. These results suggest that RF
has an additive role to ACPA in mediating osteitis.
Additional files
Additional file 1: MRI protocol. (DOC 36 kb)
Additional file 2: Figure S1. Illustration of association between ACPA
(A), RF (B) and anti-CarP (C) and MRI-detected BME, synovitis and
tenosynovitis scores in patients with RA and UA (n = 397). Horizontal
lines represent median. Whiskers show the 10th–90th percentile. Dots
represent outliers. A BME: p = 0.001; synovitis: p = 0.776; tenosynovitis:
p = 0.99. B BME: p = 0.002; synovitis: p = 0.19; tenosynovitis: p = 0.26.
C BME: p = 0.017; synovitis: p = 0.085; tenosynovitis: p = 0.056. Total
score: sum of scores in MCP, wrist, and MTP joints. MRI magnetic
resonance imaging, ACPA anti-citrullinated protein antibodies, RF
rheumatoid factor, anti-CarP anti-carbamylated protein antibodies,
BME bone marrow edema. *Significant difference between autoantibody-
negative and autoantibody-positive patients (p < 0.05). (JPG 76 kb)
Additional file 3: Figure S2. Association between ACPA level and BME
scores. Association between ACPA level and BME scores within ACPA-positive
patients with early arthritis (A) (n = 141, r = 0.071, p = 0.403) and within
ACPA-positive patients with RA or UA (B) (n = 123, r = 0.034, p = 0.706).
(JPG 24 kb)
Additional file 4: Figure S3. BME scores of ACPA-positive patients with
RA or UA (n = 123) with low, intermediate, or high levels of ACPA. Horizontal
lines represent median. Whiskers show the 10th–90th percentile. Dots represent
outliers. Baseline ACPA levels are shown categorically as low, intermediate, or
high. The groups were as follows: low ≥7 U/ml, intermediate ≥167 U/ml, and
high ≥327 U/ml. Low: n = 57; intermediate: n = 27; high: n = 39. ACPA
anti-citrullinated protein antibodies, BME bone marrow edema. Kruskal-Wallis
test, p = 0.23. (JPG 19 kb)
Additional file 5: Figure S4. Measures of disease activity in patients
with RA and UA (n = 397) with different combinations of ACPA, RF and
anti-CarP. Association between CRP (A), ESR (B), SJC (C) and DAS28 (D)
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and different autoantibody combinations. Horizontal lines represent
median. Whiskers show the 10th–90th percentile. Dots represent outliers.
ACPA anti-citrullinated protein antibodies; RF: rheumatoid factor; anti-CarP:
anti-carbamylated protein antibodies, CRP C-reactive protein, ESR erythrocyte
sedimentation rate, SJC swollen joint count based on 66 joints, DAS28
disease activity score in 28 joints. *Significant difference between
subgroups (p < 0.05). (JPG 104 kb)
Abbreviations
ACPA, anti-citrullinated protein antibodies; anti-CarP, anti-carbamylated
protein antibodies; BME, bone marrow edema; CRP, C-reactive protein;
DMARD, disease-modifying-antirheumatic-drug; EAC, Early Arthritis Clinic;
ELISA, enzyme-linked immunosorbent assay; ESR, erythrocyte sedimentation
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IQR, interquartile range; MCP, metacarpophalangeal; MRI, magnetic resonance
imaging; MTP, metatarsophalangeal ; OR, odds ratio; RA, rheumatoid arthritis;
RAMRIS, rheumatoid arthritis magnetic resonance imaging scoring system; RF,
rheumatoid factor; SD, standard deviation; SJC, swollen joint count; TJC, tender
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